专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08466108B2 TFPI inhibitors and methods of use 有权
标题翻译： TFPI抑制剂和使用方法
公开(公告)号：US08466108B2
公开(公告)日：2013-06-18
申请号：US12643818
申请日：2009-12-21
申请人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
发明人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
IPC分类号： A61K38/36 , A61K38/37 , A61K38/10 , A61K38/00 , A61K38/04 , A61K38/16 , C07K14/745 , C07K14/755
CPC分类号： C07K14/4703 , A61K38/00 , A61K47/551 , A61K47/557 , A61K47/60 , C07K7/08 , C07K14/001 , Y02A50/463
摘要： The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
摘要翻译：本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成和/或治疗受试者的血液凝固障碍。

2. 发明申请

US20100173847A1 TFPI INHIBITORS AND METHODS OF USE 有权
标题翻译： TFPI抑制剂及其使用方法
公开(公告)号：US20100173847A1
公开(公告)日：2010-07-08
申请号：US12643818
申请日：2009-12-21
申请人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
发明人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
IPC分类号： A61K38/10 , C07K7/08 , A61P7/02
CPC分类号： C07K14/4703 , A61K38/00 , A61K47/551 , A61K47/557 , A61K47/60 , C07K7/08 , C07K14/001 , Y02A50/463
摘要： The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
摘要翻译：本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成和/或治疗受试者的血液凝固障碍。

3. 发明授权

US08450275B2 TFPI inhibitors and methods of use 有权
公开(公告)号：US08450275B2
公开(公告)日：2013-05-28
申请号：US13026070
申请日：2011-02-11
申请人： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
发明人： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
IPC分类号： A61K38/57
CPC分类号： A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
摘要： The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

4. 发明授权

US08632991B2 Methods and compositions for treating bleeding disorders 有权
标题翻译：治疗出血性疾病的方法和组合物
公开(公告)号：US08632991B2
公开(公告)日：2014-01-21
申请号：US13006396
申请日：2011-01-13
申请人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
发明人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
IPC分类号： A61K51/00 , G01N33/86 , A61K49/00 , C12Q1/56
CPC分类号： G01N33/86 , A61K31/737 , A61K38/36 , A61K38/37 , Y10T436/106664 , Y10T436/107497 , Y10T436/178459 , Y10T436/18 , Y10T436/255 , A61K2300/00
摘要： Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
摘要翻译：本发明的方面包括用于增强受试者血液凝固的方法。在根据某些实施方案的实践方法中，将一定量的非抗凝血硫酸多糖（NASP）施用于受试者以增强受试者的血液凝固。还提供了制备具有凝血增强活性的NASP组合物的方法。还描述了用于本发明的实践方法的组合物和试剂盒。

5. 发明授权

US08435792B2 Methods and compositions for treating bleeding disorders 有权
公开(公告)号：US08435792B2
公开(公告)日：2013-05-07
申请号：US13111684
申请日：2011-05-19
申请人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
发明人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
IPC分类号： G01N33/86 , C12Q1/56 , A01N43/04
CPC分类号： G01N33/86 , A61K31/737 , A61K38/36 , A61K38/37 , Y10T436/106664 , Y10T436/107497 , Y10T436/178459 , Y10T436/18 , Y10T436/255 , A61K2300/00
摘要： Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

6. 发明申请

US20110244478A1 Methods and Compositions for Treating Bleeding Disorders 有权
标题翻译：治疗出血障碍的方法和组成
公开(公告)号：US20110244478A1
公开(公告)日：2011-10-06
申请号：US13111684
申请日：2011-05-19
申请人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
发明人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
IPC分类号： G01N33/566 , C08B37/00 , C12Q1/56 , C12P19/04
CPC分类号： G01N33/86 , A61K31/737 , A61K38/36 , A61K38/37 , Y10T436/106664 , Y10T436/107497 , Y10T436/178459 , Y10T436/18 , Y10T436/255 , A61K2300/00
摘要： Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
摘要翻译：本发明的方面包括用于增强受试者血液凝固的方法。在根据某些实施方案的实践方法中，将一定量的非抗凝血硫酸多糖（NASP）施用于受试者以增强受试者的血液凝固。还提供了制备具有凝血增强活性的NASP组合物的方法。还描述了用于本发明的实践方法的组合物和试剂盒。

7. 发明申请

US20110172156A1 METHODS AND COMPOSITIONS FOR TREATING BLEEDING DISORDERS 有权
标题翻译：治疗瘫痪疾病的方法和组合
公开(公告)号：US20110172156A1
公开(公告)日：2011-07-14
申请号：US13006396
申请日：2011-01-13
申请人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
发明人： Michael Dockal , Hartmut Ehrlich , Friedrich Scheiflinger
IPC分类号： A61K38/36 , A61K31/737 , A61K38/37 , C07H5/10 , A61P7/02
CPC分类号： G01N33/86 , A61K31/737 , A61K38/36 , A61K38/37 , Y10T436/106664 , Y10T436/107497 , Y10T436/178459 , Y10T436/18 , Y10T436/255 , A61K2300/00
摘要： Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
摘要翻译：本发明的方面包括用于增强受试者血液凝固的方法。在根据某些实施方案的实践方法中，将一定量的非抗凝血硫酸多糖（NASP）施用于受试者以增强受试者的血液凝固。还提供了制备具有凝血增强活性的NASP组合物的方法。还描述了用于本发明的实践方法的组合物和试剂盒。

8. 发明授权

US09566364B2 Preparations based on fibrinogen and sulfated polysaccharides 有权
标题翻译：基于纤维蛋白原和硫酸化多糖的制剂
公开(公告)号：US09566364B2
公开(公告)日：2017-02-14
申请号：US12636620
申请日：2009-12-11
申请人： Michael Dockal , Friedrich Scheiflinger , Hans Christian Hedrich , Klaus Tschetschkowitsch , Andreas Goppelt
发明人： Michael Dockal , Friedrich Scheiflinger , Hans Christian Hedrich , Klaus Tschetschkowitsch , Andreas Goppelt
IPC分类号： A61L24/10 , A61L24/08 , A61L24/04
CPC分类号： A61L24/106 , A61L24/043 , A61L2400/04
摘要： The present invention provides a preparation comprising fibrinogen and a sulfated polysaccharide as a one component composition or as a kit of parts comprising fibrinogen and sulfated polysaccharide as separated components.The present invention further provides a fibrin clot like structure obtainable by a defined process, a hemostatic patch, a two-component syringe system and various uses of the described preparations, fibrin clot like structures and patches.
摘要翻译：本发明进一步提供可通过限定的方法获得的纤维蛋白凝块样结构，止血贴剂，双组分注射器系统以及所述制剂，纤维蛋白凝块样结构和贴剂的各种用途。

9. 发明申请

US20120077749A1 Biologically Active Peptides 有权
标题翻译：生物活性肽
公开(公告)号：US20120077749A1
公开(公告)日：2012-03-29
申请号：US13238751
申请日：2011-09-21
申请人： Friedrich Scheiflinger , Michael Dockal
发明人： Friedrich Scheiflinger , Michael Dockal
IPC分类号： A61K38/08 , C07K7/64 , A61P7/04 , C07K7/08 , C07K1/04 , C07K7/06 , C07K2/00
CPC分类号： C07K7/06 , A61K38/00 , C07K1/04 , C07K7/08 , C07K14/755 , Y02P20/55
摘要： A peptide or peptide derivative comprising: (i) WDLYFEIVW;(SEQ ID NO: 1) (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
摘要翻译：一种肽或肽衍生物，其包含：（i）WDLYFEIVW; （SEQ ID NO：1）（ii）在WDLYFEIVW（SEQ ID NO：1）中包含一个，两个，三个或四个L-氨基酸取代的变体氨基酸序列; 或（iii）部分（i）和（ii）中任一项的肽或肽衍生物的逆转型变体，其中所述肽或肽衍生物具有促凝活性。一种肽或肽衍生物，其包含：（i）包含成纤维细胞的氨基酸序列; 或（ii）在成纤维细胞中包含一个，两个，三个，四个，五个或六个氨基酸取代的变体氨基酸序列，其中所述肽或肽衍生物具有促凝活性。

10. 发明申请

US20110110921A1 Methods for Treating Bleeding Disorders 有权
标题翻译：治疗出血障碍的方法
公开(公告)号：US20110110921A1
公开(公告)日：2011-05-12
申请号：US13002501
申请日：2009-08-21
申请人： Michael Dockal , Friedrich Scheiflinger , Peter Turecek
发明人： Michael Dockal , Friedrich Scheiflinger , Peter Turecek
IPC分类号： A61K31/737 , A61K31/727 , A61K38/48 , A61K38/37 , A61K38/36 , C12Q1/56 , A61P7/04
CPC分类号： A61K31/737 , A61K31/727 , A61K38/36 , A61K38/366 , A61K38/37 , A61K38/4846 , A61K38/4853 , A61K45/06 , G01N33/86 , A61K2300/00
摘要： A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor XI; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor XI-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.
摘要翻译：一种需要增强血液凝固的受试者中因子XI依赖性血液凝固增强的方法，包括向受试者施用治疗有效量的包含非抗凝血硫酸多糖（NASP）的组合物。一种需要增强血液凝固的受试者中因子XI依赖性血液凝固增强的方法，包括：（i）选择不是因子XI缺陷的受试者; 和（ii）向所述受试者施用治疗有效量的包含非抗凝血硫酸多糖（NASP）的组合物，其中所述NASP以因子XI依赖性方式增强血液凝固。一种鉴定能够根据FXI增强血液凝固的非抗凝血硫酸多糖（NASP）的方法，所述方法包括：a）将包含活化能力的FXI的血液或血浆样品与包含硫酸化多糖的组合物和测量血液或血浆样品的凝血酶或凝血酶产生参数; b）将活化受体FXI中缺乏的相应血液或血浆样品与包含硫酸化多糖的组合物结合并测量血液或血浆样品的凝血酶或凝血酶产生参数; 和c）比较步骤（a）和（b）中确定的血液或血浆样品的凝血酶或凝血酶产生参数，其中血液样品的凝血时间的降低或峰值凝血酶的增加或减少在包含活化能力的FXI的血浆样品的峰值时间与血液样品的凝血时间或峰值凝血酶相比，或者在活化能力FXI中缺乏的血浆样品的峰值时间指示NASP，其能够依赖于 FXI。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式